Abstracts
Convention Abstracts
The numbered abstracts, corresponding to their poster board number, are divided into three sections: Original Research, Quality Improvement Evaluations, and Case Reports. Within each section, the abstracts are in alphabetical order based in the lead author’s last name. ORIGINAL RESEARCH (Note the abstract number corresponds to the poster board on which the investigation/ case report is summarized.)
GPA. This assessment may prove useful in admissions decisions but could also be modified to potentially improve predictive utility.
1. Title: Predictive Value of an Admissions Interview Day Calculations Assessment Authors: Courtney L. Bradley, PharmD, BCACP; Christina H. Sherrill, PharmD, BCACP, Earle “Buddy” Lingle, PhD Institution: High Point University, Fred Wilson School of Pharmacy, High Point, NC
2. Title: Utilization of Serum Uric Acid Levels for Gout Management in an Internal Medicine Clinic Authors: Alison L.P. Compton, PharmD Candidate, Jamie Cavanaugh, PharmD, CPP, BCPS, Timothy J. Ives, PharmD, MPH, FCCP, CPP, Betsy Shilliday, PharmD, CDE, CPP, BCACP, FASHP Institution: Eshelman School of Pharmacy, and Division of General Medicine and Clinical Epidemiology, Department of Medicine, School of Medicine, The University of North Carolina at Chapel Hill
Objective: To determine the predictive value of pre-admission criteria on performance during the first semester of a four-year pharmacy program, focusing on an interview day calculations assessment and a required one-credit hour calculations course. Methods: Pre-admission data were gathered using PharmCAS applications and interview day assessments. Pre-admission variables included age; gender; ethnicity; race; attendance at a four-year institution; previous degree awarded; total credit hours; number of pre-admission course failures; PCAT composite, chemistry, and quantitative scores; total, pre-requisite, and math GPA; and admissions interview day calculations assessment. Postadmission data included overall first semester GPA and average percent for calculations course assessments, which were gathered using Learning Management Software and Dean’s Office reports. The study was determined to be exempt by High Point University Institutional Review Board. Results: Data were analyzed for all students who matriculated in Fall 2016 (N=59). Eight pre-admissions factors (gender, race, PCAT composite, PCAT chemistry, PCAT quantitative, total GPA, pre-requisite GPA, and admissions interview day calculations assessment) demonstrated correlation to average percent in calculations course assessments. A multivariable regression using PCAT composite, PCAT chemistry, PCAT quantitative (highest scores), total GPA, and admissions interview day calculations assessment provided an R-squared value of 0.425 (p<0.001). The admissions interview day calculations assessment was not correlated to first semester GPA. Conclusion: The admissions interview day calculations assessment was positively correlated with success in a first semester calculations course but not overall first semester
Objective: To compare gout management using serum uric acid monitoring and subsequent presence of pharmacotherapy within an academic internal medicine clinic to the American College of Rheumatology 2012 Guidelines. Comparison was made to the minimum frequency interval of every 6 months and a serum uric acid goal of ≤ 6 mg/dL. Methods: This retrospective chart review study was approved by the UNC Office of Human Research Ethics. Patients diagnosed with gout that had ≥ 1 clinic visit(s) and ≥ 1 serum uric acid level(s) during the study period (May 2014 - May 2016) were included. Exclusion criteria were pregnancy during the study period, or allergy to allopurinol or febuxostat. For uric acid results > 6 mg/dL, the medication list was evaluated for the presence of a urate lowering therapy (ULT) within 5 weeks of the result. Results: 454 patients had a diagnosis of gout, of which 170 had ≥ 1 serum uric acid level(s). 163 were included after application of exclusion criteria. The most recent serum uric acid level was > 6 mg/dL in 111 patients (71.8%). ULT was present on the medication list within 5 weeks of a serum uric acid level result > 6 mg/dL in 56.3% (112/199) of cases. Allopurinol was the ULT agent in 85.7% (96/112) of cases at a mode dose of 100 mg and a median of 186 mg. Among those with a level > 6 mg/dL during the study period, the frequency of serum uric acid monitoring was 0.5 checks per patient per 6 months. Conclusion: Serum uric acid monitoring was less frequent in this study population than guideline recommendations, and a ULT was not present nearly half of the time, provid33
